Vivan Therapeutics has received regulatory approval to begin a clinical registration study of its AI-enabled precision oncology software, TuMatch™, at Burjeel Cancer Institute in Abu Dhabi.
The Hub71 startup said the prospective study will evaluate TuMatch™ in patients with colorectal cancer. Led by Prof. Humaid Al Shamsi, the study will enroll at least 10 patients at the Abu Dhabi site.
TuMatch™ compares a patient’s tumour genomic profile with Vivan’s drug-response dataset and published clinical evidence, producing ranked treatment options for oncologists. The study will also collect health economics and value-based care data to support future reimbursement discussions and adoption across the UAE health system.
The company said the approval is among the first regulatory clearances in Abu Dhabi for an oncology study involving this class of software. The study is part of a wider clinical programme that includes a planned multicentre study in pancreatic and other gastrointestinal cancers across Europe and the GCC.
Vivan said data from these studies will support future CE mark and FDA submissions for TuMatch™. The company was founded by Laura Towart, who also serves as CEO.
Source: Hub71
